Growth-hormone-releasing hormone ELISA Kit (DEIABL232)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
2x96T
Sample
biological matrices
Species Reactivity
human
Intended Use
The GHRH ELISA kit is competitive enzyme immunoassay technique for in vitro quantitative measurement of GHRH in biological mtrices. This user-friendly assay design utilizes high specific monoclonal antibody to capture GHRH in sample competitively in presence of biotinylated GHRH.
Storage
Store the unopened kit at 2-8°C.
Precision
Intra-assay precision (CV%): 6% - 14%. Inter-assay precision (CV%): 16%.
Detection Limit
7.3 pg/mL

Citations


Have you cited DEIABL232 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Authors: Gasco, V.; Roncoroni, L.; Zavattaro, M.; Bona, C.; Berton, A.; Ghigo, E.; Maccario, M.; Grottoli, S.

Purpose Uncertainties exist about the predictors of the severity of the clinical picture of GH deficiency (GHD) syndrome. Aim of the study was to evaluate, in adult patients with GHD, the predictors of the development of hypercholesterolemia, hypertension, diabetes mellitus, and osteoporosis. Methods We retrospectively studied 327 adult patients (age 47.1 +/- 17.1 years) with untreated severe GHD (mean follow-up 110.9 +/- 56.8 months). GHD was defined by GHRH + arginine test using BMI cut-offs. The possible development of hypercholesterolemia, hypertension, diabetes mellitus, and osteoporosis was investigated by Kaplan-Meier survival analysis. For each clinical outcome, either a univariate or multivariate analysis according to the Cox proportional-hazards model was performed to identify those factors that were associated with the development of the event. Results GH secretion parameters were not associated with the outcomes. Hypercholesterolemia was positively and negatively predicted by a BMI >= 30 kg/m(2) (HR 2.50, p 0.00) and the dose of l-thyroxine possibly in place (HR 0.98, p 0.02), respectively. Hypertension was positively predicted by a BMI >= 30 kg/m(2) (HR 2.64, p 0.00) and IGF-I SDS values (HR 2.26, p 0.00). Diabetes mellitus was positively predicted by hypertension (HR 11.76, p 0.01). Osteoporosis was positively and negatively predicted by hypercholesterolemia (HR 3.25, p 0.01) and hypertension (HR 0.21, p 0.00), respectively. Conclusions The severity of the impairment of GH secretion does not predict the development of the clinical picture of GHD syndrome: untreated adult GHD does not increase the development of metabolic risk factors in hypopituitaric patients.

Cross-talk between GHRH and EGFR in triple-negative breast cancer cells

FEBS JOURNAL

Authors: Vacas, E.; Valenzuela, P.; Schally, A. V.; Carmena, M. J.; Prieto, J. C.; Bajo, A. M.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket